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and at the Erasmus Medical Center. He obtained his PhD in 1996 at the Erasmus University
Rotterdam (cum laude). His research focuses on decision making, in particular how people
value their health. Han Bleichrodt has received several prestigious research grants, most
recently a VICI grant from the Netherlands Organization for Scientific Research (NWO). 
Recently the Council for Public Health and Health Care, the main advisory body of the
Dutch government on health policy, recommended that only treatments costing less than
€80,000 to let a patient live an extra year in good health should be reimbursed. The
oration explains that this recommendation is sensible. Criticism that the recommendation
is merely a cost-cutting device or that human life is priceless is unwarranted.
Unfortunately, the current methods of health economics are unreliable and underestimate
the burden of impaired health. The oration shows how we can improve our methods and
reliably value health by applying recent insights from psychology. These improvements
can be obtained free of charge: no extra data need to be collected.
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4Samenvatting
Onlangs adviseerde de Raad voor de Volksgezondheid en Zorg (RVZ), het belang -
rijkste adviesorgaan van de Nederlandse regering op het gebied van gezondheids -
zorgbeleid, dat alleen die behandelingen voor vergoeding in aanmerking komen, die
minder dan €80.000 kosten om een patiënt een jaar langer in goede gezondheid te
laten leven. Dit is een goed voorstel. Het gebruiken van een dergelijke waarde wordt
vaak gezien als een bezuinigingsmiddel, maar is het zeker niet. Een harttransplantatie,
bijvoorbeeld, kost veel, maar levert voldoende gezondheidswinst op om aan het
criterium van de Raad te voldoen. Ook het argument dat we geen waarde aan menselijk
leven kunnen toekennen, is ongegrond. In ons dagelijks leven maken we voortdurend
keuzes die een verhoogd risico op overlijden met zich meebrengen.
Het hanteren van een expliciete waarde voor gezondheid, zoals in Engeland en de
Verenigde Staten gebeurt, leidt tot een betere besteding van publieke middelen.
Bovendien worden gemaakte keuzes in de gezondheidszorg zichtbaarder. De bestaande
methoden die gezondheidseconomen hanteren, zijn echter niet betrouwbaar en
onderschatten de ziektelast. Dit is eenvoudig te verhelpen door recente inzichten uit de
psychologie toe te passen. Deze rede laat zien hoe we gezondheid op een betrouwbare
manier kunnen waarderen, waarbij expliciete aandacht is voor kwaliteit van leven.
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5Summary
Recently the Council for Public Health and Health Care, the main advisory body of
the Dutch government on health policy, recommended that only treatments costing
less than €80,000 to let a patient live an extra year in good health should be
reimbursed. This recommendation is sensible. Criticism that the recommendation is
merely a cost-cutting device is unwarranted. A heart transplant, for instance, is very
expensive but yields sufficient benefits to pass the test set by the Council. The argument
that we cannot assign a value to human life is also unfounded. In our daily lives we
often make trade-offs between risks of death and other considerations.
The use of an explicit value of health, as in the US and the UK, leads to better and
more transparent health policy decisions. Unfortunately, the current methods of health
economics are unreliable and underestimate the burden of impaired health. This
oration shows how we can improve our methods and reliably value health by applying
recent insights from psychology. These improvements can be obtained free of charge: no
extra data need to be collected.
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9Introduction
Ladies and Gentlemen,
Welcome,
Usually, an oration marks the beginning of a new professor’s career. In my case, as I
took my time to give this address, it also marks the end of my appointment at the DSW
chair at the Erasmus Medical Centre. I am grateful to DSW for funding my chair. For
those of you concerned about my well-being: my appointment at the Department of
Economics has just been extended so this address still celebrates a new start.
Today we will talk about choices, choices about life and death. We do not think about
such choices everyday, but there are times where we face them. Today will be one of
these.  
Suppose your doctor has just told you that you suffer from kidney failure. There are
two treatments available, illustrated in Figure 1. The first treatment is dialysis. Patients
who opt for dialysis live for another 10 years. Half of these patients react well to the
dialysis and are almost symptom-free (we call this minor health problems). The other
half do not react well and have major health problems. That means you are restricted in
your daily activities.
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The other treatment is kidney transplant. Of the patients who take a transplant 1 out of
10 die within a week after surgery. Of those who survive 3 out of 10 lose the transplanted
kidney within the next year and then have major health problems. Those who keep the
kidney live for 12.5 years in good health. Which treatment would you choose? Is there
anyone who can answer this question now? Most of us, including myself, probably can’t. 
Figure 1 – Treatment Decision
Governments also face choices. Medical technology changes rapidly and new treat -
ments become available all the time. How does the government decide which
treatments to reimburse? Of course, if the new treatment is both cheaper and leads to
larger health improvements than what’s currently available then the government
should go for it. Similarly, if the new treatment is more expensive and gives smaller
health improvements than what’s available then the treatment should be discarded.
But what if the treatment is more expensive but yields larger improvements in health?
How does the government decide that these additional benefits are sufficiently in
balance with the higher costs?
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We, health economists, are increasingly involved in making such choices. In many
countries,economic evaluations are now required before a new treatment is reimburs -
ed. Is this justified? Are health economists up to their task? Are our methods sufficiently
fine to address the important questions that patients and societies face? 
My central thesis is that the answer to these questions is is ‘no’. No, the current tools
of health economics are unreliable and lead to the wrong treatment recommendations.
That is the dark side of my talk. But, it is no reason for despair. The bright side of my talk
will show how we can improve our tools and come up with recommendations that
better reflect the interests of patients and society. These improvements are based on
new insights from theoretical economics. They have not been used in health economics
yet. Health economics is an applied field of research and many health economists are
not well aware of developments in theory. 
But, thanks to the pioneering work of the rector and the previous deans of the
departments of economics, Harry Commandeur, and health policy and management,
Frans Rutten, we, Eddy van Doorslaer, Peter Wakker, and myself, are currently building a
health economics group in Rotterdam that is pre-eminently able to bridge the gap
between economic theory and applied health economics research. It is my conviction
that Rotterdam can become, and maybe to some extent already is, a world leader in this
field. 
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€ 80,000 for a life-year
Before I come to my main topic let me sketch a bit of history. About two years ago, the
Dutch Council for Public Health and Health Care, the most important advisory body of
the Dutch government on health policy, recommended that only treatments that cost
less than €80,000 to let a patient live an extra year in good health should be eligible for
reimbursement (RvZ 2006). The Council is not alone in its advice. In several other
countries similar guidelines are common. The most notable case is the UK where such a
benefit-cost ratio is required for any treatment that wants to be included in the NHS,
the National Health Service.
Figure 2 – Total expenditures on health care per capita in US$ PPP
An underlying reason for this recommendation is displayed in the above graph
(Figure 2). It depicts the evolution of health care expenditures per head and adjusted
for inflation in the Netherlands, the orange line, and the US, the blue line, from the
early 1960s until now. In the Netherlands, health care expenditures per head rose from
B&T28416 - Erim Binnen Oratie Bleichrodt 22dec08
about $300 per head in 1960 to more than $3000 per head now. A tenfold increase. In
the US the situation is even more dramatic with a more than twentyfold increase to
nearly $7000 per head now. What is more, the increase in health care expenditures
seems to accelerate. The health budget will come under increasing pressure in the
future due to the rapid development of medical innovations, increasing expectations
of what medical care can achieve, and the ageing of society.
It is against this background that the Council came to its advice. The health care
budget is limited and we cannot fund everything that is medically possible. Choices
have to be made. In making these choices, the Council recommends pursuing those
activities that maximize the benefits of health care. If we have €200,000 to spend then
it is better to reimburse a treatment that gains years in good health at a cost of €50,000
than one that does so at a cost of €100,000.
13
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Misguided criticism
This may sound obvious, but the Council’s recommendation was nevertheless
received with much criticism. Most of this made little sense.
The first criticism, voiced in nearly all Dutch newspapers, reflected a misunder -
standing. Commentators thought that expensive treatments should no longer be
reimbursed. The advice was perceived as a device to cut costs. This is clearly not true. The
Council said that medical programs that cost less than €80,000 to gain a year in good
health should be reimbursed. The recommendation involves both a cost and a benefit
side. A heart transplant, for example, is a very expensive treatment. But, it generates
sufficiently many extra years in good health to pass the criterion set by the Council. 
A second group of critics came from ethics. They took issue with attaching a
monetary value to a year in good health. They argued that human life is priceless and
that we can never put a price tag on it. Judging from his recent public statements, this
view is shared by the current Dutch secretary of health, Ab Klink. That’s too bad. Saying
that human life is priceless sounds perhaps appealing at first hearing. But it does not
stand scrutiny. It does not provide any guidance when we have to decide which
treatments to fund. 
Moreover, it conflicts with reality. In our daily lives we often make trade-offs
between risks of death and other considerations. Many workers take up risky jobs in
exchange for extra pay. If they considered their lives to be infinitely valuable they would
never do so. Similarly, most of you probably arrived here by car. If you consider your life
infinitely valuable then this was a very unwise decision. I strongly urge you to return by
public transport because this markedly reduces your risk of being involved in a fatal
accident. Those of you who came by bicycle probably did not wear a helmet:
irresponsible if your life is infinitely valuable. Just in case you have second thoughts, I
have one here which you can buy for €100,000. A bargain if your life is infinitely
valuable. 
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The government also assigns a finite value to human life as it does not undertake
every road or rail safety program available. Some programs are simply considered too
expensive. In the UK and the US the value of life that is used is made explicit. For
example, the EPA, the US environmental protection agency, uses a value of life of $6.9
million. Five years ago this value was still $7.9 million. Apparently living in America has
become less valuable under George W. Bush. 
Figure 3 – George W. Bush
To the best of my knowledge no explicit value of life is used by the Dutch
government. This is unfortunate because using such a value makes government policy
much more transparent. 
A third criticism, coming from political scientists, was that reimbursement
decisions should not be taken by economists but are better left to politicians.
Apparently the argument is that the political process will ensure that everyone can
have their say and that this will lead to better decisions. I don’t think the Council had in
mind to leave health policy to economists. I agree that such a supremacy would be
undesirable. But, economists can give refreshing insights about the way public money
is spent. Let me give an example. 
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In the 1990’s researchers from Harvard University compared 500 interventions to save
lives (Tengs et al. 1995). They divided these interventions into three categories: medical
interventions, injury reduction, and environmental measures. If public money were
effectively spent then these different interventions should gain life-years at basically
similar costs. 
Table 1 – Costs to Save a Life-Year*
Type of Intervention Costs / Life-Year
Medicine $27,000
Injury Reduction $68,000
Environmental $4,000,000
* in 2007 $
This was clearly not the case. Overall, medical interventions offer the best value for
money: they cost $27,000 per life-year saved. Some measures save life-years at very low
costs or even save costs. For example, methadone provision for heroin addicts saves
more than it costs, mainly through prevented crime. Injury reduction is somewhat less
cost-effective, saving life-years at an overall cost of $68,000. The price varies wildly,
however. Seat belt laws cost only $98 for a life-year saved. Strengthening buildings in
earthquake-prone areas on the other hand costs as much as $18 million dollars. 
By far the most expensive are environmental measures. They save life-years at a cost
of 4 million dollars. There are of course exceptions. The reduction of lead in gasoline
saved more than it cost. However, in general environmental measures are expensive. For
the rector, it is perhaps interesting to know that what it costs to save a life-year through
removing asbestos in roof coatings: more than $7 million. Very cost-ineffective. So
whether the reconstruction of the aula of this university was really worth the effort….
You may be inclined to believe that these data are specific for the US, which is in
many ways special indeed. Your suspicions may be raised further when I tell you that
one of the authors of this study later went on to become a chief advisor of the current
president of the USA, who is indeed not known for his environmental credentials.
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Nevertheless, studies in Sweden and the UK showed similar patterns (Soby, Ball, and Ives
1993, Ramsberg and Sjöberg 1997). These data suggest that public money is not always
effectively spent: by shifting money, for example from pollution control to medical
interventions, we can save extra lives at no extra cost. We have to keep in mind that
many interventions have benefits other than survival. What these data show, however,
is that politics can benefit from the insights of science. Politicians who are deaf to
science waste public money.
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Is health economics up to its task?
What I have said thus far hopefully justifies that the advice of the Council is sensible.
Economic evaluations can help to make health policy more transparent. The
recommendation can only work, however, if we, health economists, are up to our task. A
critical assumption is that we have the tools to compare the benefits and costs of health
care programs in a reliable manner. In particular, it assumes that we can reliably
measure the value of health. As I already mentioned, I do not believe that our current
tools can do so. Our current tools are flawed and unreliable. 
B&T28416 - Erim Binnen Oratie Bleichrodt 22dec08
19
Current practice
To make my point, let us return to the treatment decision I started my talk with, the
choice between dialysis and kidney transplant. It’s a difficult decision because we must
balance different life durations and complex and unfamiliar health states against each
other and give due weight to the risks involved. To analyze the decision we must have a
procedure, or model as economists call it, to combine these different aspects of the
decision. The model that is commonly assumed is called expected utility. 
To use expected utility we must know what health is worth to you. We need to know
the value of health. How do we determine this? We could of course look at life duration
only. Then dialysis gives the certainty of 10 extra years and kidney transplant gives
either 12.5 extra years, or 10 extra years or nothing at all. But looking at life duration
alone does not tell the full story. Not all life-years are spent in the same health quality.
Life-years in good health count for more than life-years with major health problems. 
To capture this, we adjust life-years for the quality of life in which they are spent. The
resulting number is called a quality-adjusted life-year or QALY for short. QALYs are easy
to interpret. One QALY corresponds with one year in good health. There are many ways
in which we can gain one QALY. It can mean, for example, one more year in good health,
or two more years in health of only 50%, or 4 more years in 25%. 
A cause of concern is to what extent QALYs reflect how people perceive health. When
I use QALYs to value the health states does this indeed capture how you feel about
health? Can your feelings be captured by such a simple formula or are they more
complex? Many health economists believed that QALYs were too simple and new
measures of health have been proposed, most notably the so-called healthy-years
equivalents. In the end these new measures did not stand scrutiny. The new
developments in theoretical economics that I will discuss shortly have also led to a
reconsideration of QALYs. I believe that QALYs are fairly accurate as a reflection of how
people feel about health. They could be improved somewhat but for all practical
purposes they perform well enough.
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Problems
If QALYs are basically fine and we want to work with them, one question remains. To
use QALYs we must measure quality of life. How do we do that? Suppose I want to
measure how many QALYs one year with, say, major health problems is worth to you. The
recommended method is to give you two options. Option 1 is the certainty of living with
major health problems for the rest of your life. This means that you have difficulty
walking, are unable to participate in most leisure activities, and have moderate pain.
Option 2 is to undergo a treatment that can either succeed, in which case you live
the rest of your life in good health, or fail, in which case you die within a week. I then ask
you which risk of death you are willing to take. 0%, 5%, 10%, 20%, or even 50%? Please
give it some serious thought. Just for 20 seconds. Which is the maximum risk of death
that you are willing to take to undergo the treatment? 
In real data this maximum risk of death is about 10%. If the risk of death is less than
10%, we prefer the treatment, if it exceeds 10% we prefer to live with major health
problems. Under expected utility, this means that our value of major health problems is
90% of the value of good health. So we think major health problems are not very serious.
Their value is almost equal to good health. If we have them, we’re quite all right and a
health policy-maker should not care too much about us.
This procedure is known as the standard gamble, an unfortunate name because you
probably link the term gamble more with a casino than with a medical treatment. In
this context, the term gamble just means that the treatment is risky and offers several
possible outcomes. Because the term is so common I will continue to use it even though
it is not well-chosen.
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Is the standard gamble right? Does it measure quality of life correctly? In the above
example, is our value of major health problems indeed 90% of the value of good health?
Before I answer that question let me again sketch a bit of history. 
Daniel Bernoulli
Expected utility was introduced in the 18th century by a Swiss mathematician Daniel
Bernoulli (Bernoulli 1738). The theory has a little Dutch flavour to it as Bernoulli was born
in Groningen. Bernoulli proposed expected utility as an explanation for a behavioural
pattern that he observed. He did not give any reasons why people should behave
according to expected utility. It took more than two centuries for this to be established
by a mathematician John von Neumann and an economist Oskar Morgenstern (von
Neumann and Morgenstern 1944). 
John von Neumann Oskar Morgenstern
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Von Neumann was a brilliant man, what Einstein was for physics he was for
mathematics. He has also affected your life as he is one of the developers of the
computer. Von Neumann was a very colourful personality who was known for the wild
parties he gave at least twice a week. He was a very bad driver, mainly because he used
to read books while driving. And he was an insatiate womanizer. In Los Alamos where he
worked on the atomic bomb during World War II, the secretaries covered the open space
under their desks with cardboard to stop him from staring at their legs. No comparable
stories circulate about Morgenstern, but then he was an economist. 
Von Neumann and Morgenstern clarified why it makes sense for people to behave
according to expected utility. But, that it makes sense for people to behave according to
expected utility does not mean that they really do. Let us look again at the standard
gamble. 
We found that we are willing to take a 10% risk of death to avoid major health
problems. I told you that this means that our value of major health problems is 90% of
the value of good health, so almost perfectly healthy. A policy-maker deciding how to
spend the money should not give much priority to us. Treating us only leads to a small
gain in health. 
But is this really true? Can we deduce from our answer that the value of major
health problems is really as much as 90% of the value of good health? I don’t think so. We
believe major health problems are serious and treating these will benefit us a lot.
However, we are not willing to run a large risk of death either. What is wrong is the
conclusion that a small risk of death translates into a large value of major health
major health problems
good health
10% death within a week
vs.
90%
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problems. In other words, the standard gamble is wrong. It overestimates the value of
major health problems. Consequently, benefit-cost analyses based on the standard
gamble underestimate the burden imposed by major health problems. Consequently,
the number of QALYs that can be gained by treating these health problems will be
underestimated and too little will be spent on treating major health problems.
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“Solutions”
What now? How to solve this problem? We cannot use the standard gamble because
it gives the wrong values of health. But then what? One line of rescue comes from
psychology. It says that most people do not have well-defined preferences for health.
When you answered the standard gamble, you were asked to make a comparison to
which you probably have not given much, if any, thought before. You did not have a
ready-made answer. Instead, you were probably searching for a way to come up with a
plausible answer within 20 seconds. Your response was the sum of two terms: your
genuine preferences, which we want to know, and a term that reflects your response
strategy. To arrive at your true value of major health problems we should try to
eliminate the second term. This is not easy, however, and requires much effort. In
economic evaluations, we generally do not have the time and resources to do so. In
theory this psychological approach is the best solution to obtain reliable values of
health. In the practice of economic evaluation, however, other ways must be found to
solve our problem.
A second possibility is to discard the standard gamble altogether and to use other
methods. This is a common strategy in health economics. For the initiated, I am thinking
here about methods such as the time trade-off and the visual analogue scale.
Unfortunately these methods have their own problems. They are at best ad-hoc
solutions to the measurement problems we face, but, in my view, they cannot be taken
as the final answer.
24
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Prospect Theory
That leaves a third option, which I favour. That is to accept the answers as they are
and to make the best of them. We must try to find a way to derive more plausible values
for health from the standard gamble. To do so we must abandon expected utility. We
need a theory that better explains how people answered the standard gamble. It is here
that we apply the new insights from economics and psychology. 
Daniel Kahneman Amos Tversky
The solution is prospect theory. Prospect theory was developed by two psychologists
Daniel Kahneman and Amos Tversky (Kahneman and Tversky 1979, Tversky and
Kahneman 1992). It is the most important theory of decision-making in economics
today. In 2002 Daniel Kahneman received the Nobel prize in economics for the
introduction of prospect theory. Unfortunately Amos Tversky died in 1996 and he could
not share this honor as the Nobel prize is not awarded posthumously. Tversky was not
only a brilliant scientist, but also a decorated war hero, a rare honour amongst
scientists. His fame came for saving the life of a fellow soldier. The soldier froze in panic
after placing an explosive charge, literally lying on top of the explosive. Tversky, then 19
years old, knew the explosion would occur within a few seconds. Nevertheless, in a split
second he took the gamble and risked his life. He ran to the soldier, picked him up and
threw him to safety, only to be wounded himself. For this display of courage, Tversky
earned Israel’s highest military decoration.
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To understand how prospect theory works, let us look one final time at the standard
gamble. Under expected utility, the value of major health problems is 90% of the value
of good health. Prospect theory disputes this. It argues that expected utility has two
important problems. First, suppose I ask you how much are you willing to pay to reduce
the risk of a cancer, from 1% to zero. Is that the same amount that you are willing to pay
to reduce the risk from 5% to 4%? Expected utility says yes, but it appears that the two
reductions are not the same. It’s a different choice. Most people pay more for the former
than for the latter. We find completely eliminating risk very comforting. We want to feel
safe. 
Prospect theory has another key insight. We want a gain but we certainly do not
want to lose. So if we can win €100 when the head of a coin comes up but lose €100
when the tail comes up most of us are not willing to play. We don’t want to lose. 
These two insights imply that the standard gamble overestimates the value of
health. We don’t want to lose so we don’t want to run a large risk of death. Under our
current tools we conclude that our health problems are not serious. Prospect theory
gives us a better picture of reality. It says that our health problems are serious and that
their value is less than 90% of the value of good health. 
Figure 4 – The Value of Health under Prospect Theory
Probability of good health
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How wrong is expected utility? What’s the difference between the value of health
under expected utility and under prospect theory? Figure 4 shows this. It shows for
each answer to the standard gamble the implied value under prospect theory. The
diagonal shows the values under expected utility. The green curve, showing the values
under prospect theory, lies almost everywhere under the diagonal. In other words,
the standard gamble leads to an overestimation of the value of health. And, the
overestimation is substantial. In our standard gamble question we concluded that
the value of major health problems was 90% of the value of good health. Under
prospect theory this value is only 65% of the value of good health. A huge difference
and much more realistic.
You may retort “but is what you tell us true? Does prospect theory indeed lead to
better values for health?” A legitimate question, indeed. To answer it I will show you
some data that will give substance to my claim that the current tools of economic
evaluation are wrong and can be improved by prospect theory. 
In a study with Jose Luis Pinto and Peter Wakker (Bleichrodt, Pinto, and Wakker 2001),
we collected data for three methods that should give the same values for health when
expected utility is true. 
Figure 5 – Differences in Value under Expected Utility
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The above figure (Figure 5) shows the differences between these methods under
expected utility. The circles indicate the differences in health state values between the
first and the second method, the squares the differences between the first and the third
method and the triangles the differences between the second and the third method. If
expected utility were true there should be no differences. All points should be located
on the horizontal axis. This is clearly not the case. The points are all over the place and
expected utility is clearly wrong.
What happens under prospect theory? Figure 6 displays. The blue circles, squares
and triangles show the differences under prospect theory. The green ones show the
differences under expected utility. Under prospect theory, all differences go to zero. All
points are close to the horizontal axis. Prospect theory indeed performs much better
than expected utility.
Figure 6 – Improvement under Prospect Theory
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Conclusion
Let me conclude. Economic evaluations of health care can help to make better
medical decisions. Decisions about life and death. Our current methods are wrong. They
underestimate the burden of impaired health. Reality is different from what we did
believe. Policy decisions based on our current tools are not at all in the best interests of
patients. We, scientists, have the responsibility to bridge the gap between theory and
reality. Prospect theory respects reality. Now, we have every opportunity to obtain
reliable values of health. And, these values can even be obtained free of charge: we do
not have to collect additional data. We can apply prospect theory immediately. What
remains is to spread the word. I hope I have convinced you.
Thank you.
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Han Bleichrodt (1965) is professor of health economics at the Department of Economics
and at the Erasmus Medical Center. He obtained his PhD in 1996 at the Erasmus University
Rotterdam (cum laude). His research focuses on decision making, in particular how people
value their health. Han Bleichrodt has received several prestigious research grants, most
recently a VICI grant from the Netherlands Organization for Scientific Research (NWO). 
Recently the Council for Public Health and Health Care, the main advisory body of the
Dutch government on health policy, recommended that only treatments costing less than
€80,000 to let a patient live an extra year in good health should be reimbursed. The
oration explains that this recommendation is sensible. Criticism that the recommendation
is merely a cost-cutting device or that human life is priceless is unwarranted.
Unfortunately, the current methods of health economics are unreliable and underestimate
the burden of impaired health. The oration shows how we can improve our methods and
reliably value health by applying recent insights from psychology. These improvements
can be obtained free of charge: no extra data need to be collected.
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